Aytu Bioscience Inc (OTCMKTS: AYTU) had an incredible time in the market last week. However, more recently, the stock has been on a bit of a slide, coming off of highs. Nonetheless, if you’re concerned about what’s going on with AYTU, you shouldn’t be. The reality is that recent news has been overwhelmingly positive. If you missed it, our chief strategic analyst, Kenny Soulstring recently covered the stock in detail. You can read his analysis here. In the mean time, the big story with AYTU is sales. Here are some of the key points with regard to sales Mr. Soulstring recently brought to the attention of investors.
Natesto® Sales Are Growing For Good Reason
Natesto is a key testosterone replacement therapy offered by Aytu Bioscience. In fact, the treatment remains as the only topical testosterone replacement therapy not labeled with a Blcak Box Warning. This is largely why Natesto sales are climbing. As the only proven treatment without the known risks from treatments like AndroGel® and Axiron®. Because of this, recent sales data released by AYTU shows incredible progress. In the most recent numbers, investors learned that sales of Natesto increased by 20% between April and May. From May to June, the same 20% gain in sales was seen.
MiOXYS® Available In 20 Countries And Going For Approval In The US!
Another reason you might want to consider taking a close look at AYTU has to do with MiOXYS. The treatment is a CE marked, male infertility device that is already being sold in 20 countries. Ultimately, the diagnostic system is a first-in-class and gives physicians the ability to perform rapid in-office screening for male infertility. It’s also worth noting that the treatment is currently progressing through the United States regulatory process and toward a 501K pathway.
ProstaScint® Has Incredible Potential
Another product worth noting with regard to AYTU is ProtaScint, the FDA approved treatment for prostate cancer. This is key as the prostate cancer market is massive. In fact, the industry has grown to beyond $7 billion in 2016 from just $2.5 billion in 2011. Ultimately, the market is looking for reliable screening alternatives that can catch the disease in early stages. At the end of the day, that’s just what ProtaScint provides.
Finally, We Have Fiera®
Finally, let’s chat a bit about Fiera. This treatment is different from the others discussed as instead of focusing on men, this one focuses on women. On May 5th, 2017, AYTU acquired Nuelle, bringing along with it the rights to Fiera. Fiera is an already commercially available for women with sexual dysfunction issues, and has massive market potential. Fiera is already gaining substantial attention in the market that has an estimated 53 million women in the United States alone meeting the clinical criteria for having sexual dysfunction issues.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
The Bottom Line
The bottom line here is that the product lineup at AYTU is incredible, and with the right marketing, sales are likely to fly ahead. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!